Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AP Antivirals for treatment of HCV infections
J05AP01 Ribavirin
D00423 Ribavirin (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-hepatitis C (HCV) Agents
Ribavirin
D00423 Ribavirin (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D00423 Ribavirin (JP18/USP/INN)
Drug groups [BR:br08330]
Antiviral
DG01440 Arabinofuranosyl type antiviral
D00423 Ribavirin
DG03198 Anti-HCV agent
DG02000 HCV NS5B polymerase inhibitor
D00423 Ribavirin
Drug classes [BR:br08332]
Antiviral
DG03198 Anti-HCV agent
D00423 Ribavirin
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
HCV NS5A/NS5B inhibitor
D00423 Ribavirin (JP18/USP/INN) <JP/US>
Antimicrobials abbreviations [BR:br08327]
Antivirals
Genome replication inhibitor
HCV NS5A/NS5B inhibitor
D00423 Ribavirin (JP17/USP/INN)
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00423 Ribavirin
D00423 Ribavirin capsules
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00423
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00423
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D00423